Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 16 (Bloomberg) -- Abbott Laboratories, the largest maker of heart stents and adult nutritional beverages, raised its full-year earnings forecast after sales rose across its four major health-care businesses.

Abbott boosted by 3 cents its adjusted earnings forecast for 2014, to $2.19 to $2.29 a share. Second-quarter profit fell to $466 million, or 30 cents a share, from $476 million, or 30 cents, a year earlier, the Abbott Park, Illinois-based company said in a statement today.

Abbott is fine-tuning its businesses 18 months after splitting off its brand-name pharmaceutical unit. On July 14, the company announced it would sell its generic drug business for developed markets to Mylan Inc. At the same time, Abbott is expanding sales of those drugs in emerging markets, with deals such as the purchase of Chile’s CFR Pharmaceuticals in May.

“We’re ahead of our expectations through the first half of the year and are raising our earnings-per-share guidance range as we continue to shape the company for long-term growth,” said Chief Executive Officer Miles White in the statement. White said on a call with analysts that he expected sales to grow faster during the second half of the year.

Earnings excluding one-time items were 54 cents a share, beating by 3 cents the average of 20 analyst estimates compiled by Bloomberg. Revenue increased to $5.55 billion, from $5.45 billion last year, beating estimates for the first time in the past 18 months.

Optics Demand

All four business groups saw sales increase, led by demand for medical optics in the devices unit that surged 12 percent. Sales of branded generic drugs sold in emerging markets rose 4 percent, adult nutrition sales were up 4 percent, and diagnostics increased 5 percent.

“Abbott has been a bit of a ‘show me’ story in the last few quarters as the company worked through headwinds in its established products and nutritionals businesses,” said Danielle Antalffy, an analyst at Leerink Partners in New York. After beating expectations, raising guidance and bolstering its portfolio, “Abbott may be nearing a potential sales growth inflection point,” she wrote in a note to clients today.

Abbott fell less than 1 percent to $41.05 at 4 p.m. in New York. The shares have risen 15 percent in the last 12 months.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at

To contact the editors responsible for this story: Reg Gale at Drew Armstrong

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.